Medically reviewed by Ritchie Stevens, MD, Radiation Oncologist on June 8, 2026.
Adaptive radiotherapy for liver cancer
The liver is one of the most mobile organs in the body, shifting 10–30 mm with every breath. Conventional radiation must use wide margins to account for this motion — exposing healthy liver tissue the patient needs for survival. Adaptive SBRT on the Akesis Gemini 360 re-images the liver at every session and recalculates the plan to treat the tumor where it actually is, preserving the maximum amount of functional liver.
Why Liver Cancer needs more than a fixed plan
Delivering radiation to the liver is uniquely demanding. These three challenges explain why adaptive capability matters more for liver cancer than almost any other site.
Massive respiratory motion
The liver shifts 10–30 mm superiorly and inferiorly with each breath cycle — the largest organ motion of any abdominal structure. A conventional plan built on a single-moment CT cannot account for this continuous movement.
Liver function preservation
Unlike most organs, the liver cannot spare much reserve. Patients with hepatocellular carcinoma often have underlying cirrhosis, making liver function preservation critical. Wide radiation margins that irradiate healthy hepatic parenchyma risk radiation-induced liver disease.
Proximity to hollow viscera
The stomach, duodenum, and colon lie immediately adjacent to the liver. These radiation-sensitive structures are easily damaged if the plan cannot tightly conform to the liver tumor's exact daily position.
What the evidence shows
SBRT for liver tumors has accumulated robust prospective evidence over the past two decades, establishing high local control rates with an acceptable toxicity profile.
Bujold et al.: 87% 1-year local control for HCC
This prospective phase 1–2 dose escalation study treated 102 patients with hepatocellular carcinoma using SBRT. At one year, local control was 87% and median overall survival was 17 months — results comparable to other local ablative therapies in patients unsuitable for resection or ablation.
doi.org/10.1200/JCO.2012.44.1659Rusthoven et al.: 92% local control for liver metastases
This multi-institutional phase 1–2 trial treated 47 patients with 1–3 liver metastases using 3-fraction SBRT. Two-year local control was 92%, with no grade 4–5 toxicity. SBRT is now considered a standard treatment option for oligometastatic liver disease.
doi.org/10.1200/JCO.2008.19.6329Child-Pugh A patients tolerate ablative doses
Multiple studies confirm that Child-Pugh A liver function is the key eligibility criterion for ablative liver SBRT. With careful dosimetric constraints on healthy liver volume, the risk of radiation-induced liver disease (RILD) can be kept below 5% in appropriately selected patients.
doi.org/10.1016/s0360-3016(02)02846-8Your treatment workflow
At 5D Cancer Services, liver SBRT is planned and delivered with the highest attention to respiratory motion management and liver function preservation.
Liver function evaluation and simulation
Pre-treatment labs assess liver function (Child-Pugh score, bilirubin, albumin). A planning CT — often with diagnostic MRI or PET fusion — is acquired. Contrast enhancement delineates the tumor boundary from surrounding hepatic parenchyma.
Dosimetric planning with liver constraints
The plan is optimized to deliver ablative dose to the tumor while keeping healthy liver volume within published tolerance limits — typically constraining the volume of liver receiving more than 15–21 Gy to protect functional reserve.
Daily CBCT adaptation (sessions 1–5)
At each session, a CBCT localizes the liver tumor's current position relative to the treatment isocenter. The Gemini 360 shifts and adapts the plan to match, then delivers the beam. Sessions typically take 30–50 minutes.
Imaging follow-up at 1, 3, and 6 months
CT or MRI with contrast is used to assess local response at 4–6 weeks after the final fraction, then every 3 months for the first year. AFP is monitored in HCC patients. Local control is typically confirmed by 3 months post-treatment.
Adaptive vs. conventional radiation
| Factor | Adaptive RT (Gemini 360) | Conventional Radiation |
|---|---|---|
| Total sessions | 3–5 sessions over 1–2 weeks | 15–28 sessions over 3–6 weeks |
| Daily imaging | CBCT at every session | Periodic imaging only |
| Respiratory management | Daily plan adaptation to liver position | Large ITV or breath-hold technique |
| Healthy liver preservation | Tight margins protect functional parenchyma | Wider margins irradiate more healthy liver |
| Local control (HCC) | ~87–90% at 1 year | ~70–80% with standard IMRT |
| RILD risk | Minimized with tight dosimetric constraints | Higher with larger irradiated volumes |
Frequently asked questions
Can adaptive SBRT treat hepatocellular carcinoma (HCC)?
Yes. Adaptive SBRT is an effective local treatment for HCC in patients who are not candidates for surgical resection, transplant, or thermal ablation — or whose tumors are not accessible to ablation. Child-Pugh A liver function and adequate healthy liver volume are the primary eligibility criteria.
Can liver metastases from colon, breast, or lung cancer be treated?
Yes. Adaptive SBRT for liver metastases is well-supported by prospective data, with 2-year local control rates above 90% in properly selected patients. One to three liver lesions can typically be treated in a single SBRT course.
How does breathing motion affect liver treatment?
The liver shifts 10–30 mm vertically with each breath. The Gemini 360 captures the tumor's exact position before each fraction via CBCT and adapts the plan accordingly. This eliminates the large motion margins required by conventional approaches, protecting healthy hepatic parenchyma from unnecessary radiation.
What is radiation-induced liver disease (RILD) and how is it avoided?
RILD is a syndrome of liver dysfunction caused by radiation to a large volume of hepatic tissue. It is avoided by carefully constraining the volume of healthy liver that receives high doses — keeping the mean liver dose and the volume exceeding specific dose thresholds within published safe limits. The adaptive tight margins on the Gemini 360 make these constraints easier to meet.
Educational information — not medical advice
The content on this page is provided for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this site. If you think you may have a medical emergency, call your doctor or 911 immediately.
References
- 1.Bujold A, Massey CA, Kim JJ, et al. Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma. J Clin Oncol. 2013;31(13):1631–1639. doi.org/10.1200/JCO.2012.44.1659
- 2.Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases. J Clin Oncol. 2009;27(10):1572–1578. doi.org/10.1200/JCO.2008.19.6329
- 3.Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53(4):810–821. doi.org/10.1016/s0360-3016(02)02846-8
Also see: Adaptive RT by cancer type
Please do not send Protected Health Information (PHI) by email or voicemail. Standard email is not secure — call us and we will arrange a secure channel.
